Heron Therapeutics

Heron announces FDA approval of Sustol for chemotherapy-induced nausea

Thursday, August 11, 2016

Heron Therapeutics has announced that the FDA has approved SUSTOL (granisetron) extended-release injection. SUSTOL is a serotonin-3 (5-HT3) receptor antagonist indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens.

[Read More]